MCID: OVR078
MIFTS: 50

Ovarian Cancer, Somatic malady

Categories: Genetic diseases (common), Cancer diseases

Aliases & Classifications for Ovarian Cancer, Somatic

About this section

Aliases & Descriptions for Ovarian Cancer, Somatic:

Name: Ovarian Cancer, Somatic 52 24 12
Adenocarcinoma, Ovarian, Somatic 52 12
Epithelial Ovarian Cancer 70 68
Malignant Neoplasm of Ovary 68
 
Ovarian Carcinoma, Somatic 52
Ovarian Carcinoma 68
Ovarian Cancer 70
Oc 70

Characteristics:

HPO:

64
ovarian cancer, somatic:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 167000
MeSH39 D010051

Summaries for Ovarian Cancer, Somatic

About this section
OMIM:52 Ovarian cancer, the leading cause of death from gynecologic malignancy, is characterized by advanced presentation with... (167000) more...

MalaCards based summary: Ovarian Cancer, Somatic, also known as adenocarcinoma, ovarian, somatic, is related to prostate cancer and vaginal adenosarcoma, and has symptoms including abnormality of metabolism/homeostasis, breast carcinoma and ovarian papillary adenocarcinoma. An important gene associated with Ovarian Cancer, Somatic is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways are VEGFR3 signaling in lymphatic endothelium and Nongenotropic Androgen signaling. Affiliated tissues include ovary and testes, and related mouse phenotypes are Decreased cell migration and respiratory system.

UniProtKB/Swiss-Prot:70 Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

Related Diseases for Ovarian Cancer, Somatic

About this section

Diseases related to Ovarian Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 103)
idRelated DiseaseScoreTop Affiliating Genes
1prostate cancer26.9AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
2vaginal adenosarcoma10.5ERBB2, PIK3CA
3trigeminal nerve disease10.4BRCA1, ERBB2
4malignant hyperthermia susceptibility type 210.4KRAS, PIK3CA
5pregnancy adenoma10.4CDH1, ERBB2
6retinitis10.4ERBB2, PIK3CA
7diffuse intrinsic pontine glioma10.4CDH1, ERBB2
8hemochromatosis type 210.3CTNNB1, PIK3CA
9epidermal nevus, somatic10.3KRAS, PIK3CA
10ovarian small cell carcinoma10.3CTNNB1, ERBB2, PIK3CA
11gastric squamous cell carcinoma10.3CDH1, ERBB2
12plethora of newborn10.3CDH1, CTNNB1
13epilepsy, progressive myoclonic 1b10.3CTNNB1, PARK2
14gliomatosis peritonei10.3AKT1, ERBB2, PIK3CA
15vocal cord scarring10.2AKT1, CTNNB1, PIK3CA
16breast papillary carcinoma10.2ERBB2, KRAS, PIK3CA
17complex lethal osteochondrodysplasia10.2CDH1, PIK3CA
18dermatosis papulosa nigra10.2ERBB2, KRAS, PIK3CA
19adenosquamous carcinoma10.2ERBB2, KRAS, PIK3CA
20microscopic colitis10.2AKT1, CTNNB1, PIK3CA
21gastric cancer risk after h. pylori infection10.2CDH1, KRAS
22trachea adenoid cystic carcinoma10.2KRAS, PIK3CA
23cholesteatoma of external ear10.2BRCA1, ERBB2
24breast malignant phyllodes tumor10.1CDH1, CTNNB1, ERBB2
25lobular neoplasia10.1CDH1, CTNNB1, ERBB2
26baraitser-winter cerebrofrontofacial syndrome10.1BRCA2, PIK3CA
27osteopetrosis10.1
28nodular degeneration of cornea10.1CTNNB1, ERBB2, KRAS
29villous adenoma10.1AKT1, CDH1, CTNNB1
30congenital pulmonary veins atresia or stenosis10.0BRCA1, BRCA2
31chorea, hereditary benign10.0CDH1, CTNNB1, PIK3CA
32bronchopulmonary dysplasia10.0BRCA1, BRCA2
33autoimmune disease of blood10.0BRCA1, BRCA2
34selective ige deficiency disease10.0BRCA1, BRCA2
35lethal congenital contracture syndrome 710.0BRCA1, BRCA2
36richter's syndrome10.0AKT1, CDH1, KRAS
37hartnup disorder10.0CDH1, ERBB2, KRAS
38zimmermann-laband syndrome 210.0AKT1, CDH1, ERBB2, PIK3CA
39tracheal disease10.0AKT1, CDH1, CTNNB1
40gastrointestinal neuroendocrine tumor9.9CDH1, CTNNB1, KRAS
41periapical granuloma9.9CDH1, CTNNB1, KRAS
42arteritic anterior ischemic optic neuropathy9.9CDH1, CTNNB1, KRAS
43fat necrosis of breast9.9BRCA1, BRCA2
44plasma protein metabolism disease9.9CDH1, CTNNB1, KRAS
45nasal cavity adenocarcinoma9.9CDH1, CTNNB1, KRAS
46amyloid tumor9.9BRCA1, BRCA2
47plasmacytoma9.9AKT1, CDH1, CTNNB1, ERBB2
48ovarian brenner tumor9.9BRCA1, BRCA2
49fallopian tube germ cell cancer9.9BRCA1, BRCA2
50papillary adenofibroma9.8BRCA1, BRCA2, PIK3CA

Comorbidity relations with Ovarian Cancer, Somatic via Phenotypic Disease Network (PDN):


Acute CystitisDeficiency Anemia
Fallopian Tube CarcinomaHydronephrosis
Intestinal ObstructionNeutropenia
Paralytic IleusProtein-Energy Malnutrition
Peritoneum Cancer

Graphical network of the top 20 diseases related to Ovarian Cancer, Somatic:



Diseases related to ovarian cancer, somatic

Symptoms & Phenotypes for Ovarian Cancer, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

167000

Clinical features from OMIM:

167000

Human phenotypes related to Ovarian Cancer, Somatic:

 64
id Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis64 HP:0001939
2 breast carcinoma64 HP:0003002
3 ovarian papillary adenocarcinoma64 HP:0006774
4 dysgerminoma64 HP:0100621

UMLS symptoms related to Ovarian Cancer, Somatic:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00055-A-19.6AKT1, CTNNB1, KRAS, PIK3CA

MGI Mouse Phenotypes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

41 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053888.6AKT1, BRCA1, CTNNB1, ERBB2, KRAS, PARK2
2MP:00030128.6CDH1, CTNNB1, KRAS, OPCML, PARK2, PIK3CA
3MP:00053698.3AKT1, BRCA1, CTNNB1, ERBB2, KRAS, PARK2
4MP:00053717.9BRCA1, BRCA2, CTNNB1, ERBB2, KRAS, PALB2
5MP:00053817.6BRCA1, BRCA2, CDH1, CTNNB1, ERBB2, KRAS
6MP:00028737.5AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
7MP:00053907.4AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
8MP:00053797.4AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
9MP:00053897.4AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
10MP:00053867.2AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
11MP:00053806.9AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
12MP:00053876.9AKT1, BRCA1, BRCA2, CDH1, CTNNB1, KRAS
13MP:00036316.6AKT1, BRCA1, BRCA2, CTNNB1, ERBB2, KRAS
14MP:00053766.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
15MP:00053846.5AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
16MP:00107716.4AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
17MP:00107686.3AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
18MP:00020066.2AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2
19MP:00053856.0AKT1, BRCA1, CDH1, CTNNB1, ERBB2, KRAS
20MP:00053785.6AKT1, BRCA1, BRCA2, CDH1, CTNNB1, ERBB2

Drugs & Therapeutics for Ovarian Cancer, Somatic

About this section

Drugs for Ovarian Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
OlaparibapprovedPhase 4, Phase 3, Phase 2126763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
2Poly(ADP-ribose) Polymerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1309
3
Fulvestrantapproved, investigationalPhase 2194129453-61-8104741, 17756771
Synonyms:
(7R,13S,17S)-13-methyl-7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7R,8S,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol
129453-61-8
7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol
7alpha-(9-((4,4,5,5,5,-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-(9-((4,4,5,5,5-Pentafluoropentyl)sulfinyl)nonyl)estra-1,3,5(10)-triene-3,17beta-diol
7alpha-[9[(4,4,5,5,5-Pentafluropentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene-3, 17 beta diol
AC-4693
AC1L2XEN
AstraZeneca brand of fulvestrant
BIDD:ER0348
BIDD:PXR0136
C070081
C32H47F5O3S
CCRIS 8741
CHEBI:404798
CHEMBL1358
CID104741
D01161
DB00947
Faslodex
Faslodex (TN)
 
Faslodex(ICI 182,780)
Faslodex, ICI 182780, Fulvestrant
Fulvestrant
Fulvestrant (JAN/USAN/INN)
Fulvestrant [USAN]
HMS2090N22
HSDB 7658
I06-1109
ICI 182,780
ICI 182,789
ICI-182780
Ici 182780
LS-64781
NCGC00164789-02
NSC719276
S1191_Selleck
UNII-22X328QOC4
ZD 182780
ZD-182780
ZD-9238
ZM 182780
ZM-182780
fulvestrant
nchembio.168-comp5
nchembio.76-comp5
nchembio775-comp4
4
Estradiolapproved, investigational, vet_approvedPhase 2128350-28-25757, 53477783
Synonyms:
(+)-3,17b-Estradiol
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17beta)-Estra-1,3,5(10)-triene-3,17-diol
.alpha.-Estradiol
.alpha.-Oestradiol
.beta.-Estradiol
.beta.-Oestradiol
1,3,5[10]-Estratriene-3,17beta-diol 3-sulfate
1,3,5[10]-Estratriene-3,17beta-diol 3-sulphate
13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol
17 beta-Estradiol
17-.BETA.-Estradiol
17-E
17-beta
17-beta-OH-estradiol
17-beta-estradiol
17.beta.-Estradiol
17.beta.-Oestradiol
17E
17b-Estradiol
17b-Oestradiol
17beta Oestradiol
17beta oestradiol
17beta-Estra-1,3,5(10)-triene-3,17-diol
17beta-Estradiol
17beta-Oestradiol
1jgl
1qkt
1qku
2d06
3,17-Epidihydroxyestratriene
3,17-beta-Estradiol
3,17-beta-Oestradiol
3,17.beta.-Estradiol
3,17b-Dihydroxyestra-1,3,5(10)-triene
3,17b-Estradiol
3,17beta-Estradiol
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulfate
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulphate
50-28-2
73459-61-7
873662-39-6
AC-10460
AC1L1L2K
Aerodiol
Agofollin
Alora
Altrad
Amnestrogen
Aquadiol
B-Estradiol
BEDOs
BIDD:ER0125
BIDD:PXR0065
BPBio1_000532
BSPBio_000482
BSPBio_001065
Bardiol
Benzhormovarine
Beta-estradiol
Bio-0812
Bio-E-Gel
Bio1_000403
Bio1_000892
Bio1_001381
Bio2_000363
Bio2_000843
C00951
C18H24O2
CCRIS 280
CHEBI:16469
CHEMBL135
CID5757
CMC_11154
CPD-352
CPD000059126
Climaderm
Climara
Climara (TN)
Climara Forte
Compudose
Compudose 200
Compudose 365
Corpagen
D-3,17beta-Estradiol
D-Estradiol
D-Oestradiol
D00105
DB00783
Dermestril
Destradiol
Dihydro-Theelin
Dihydrofollicular hormone
Dihydrofolliculin
Dihydromenformon
Dihydrotheelin
Dihydroxyesterin
Dihydroxyestrin
Dihydroxyoestrin
Dimenformon
Diogyn
Diogynets
Divigel
Divigel (TN)
E 2
E 8875
E(sub 2)
E0025
E1024_SIGMA
E1132_SIGMA
E2257_SIGMA
E2758_SIGMA
E8875_SIGMA
EINECS 200-023-8
EU-0100503
Elestrin
Encore
Epiestriol 50
Esclim
Estra-1,3,5(10)-triene-3,17b-diol
Estrace
Estrace (TN)
Estraderm
Estraderm (TN)
Estraderm MX
Estraderm TTS
Estraderm TTS 100
Estraderm TTS 50
Estradiol
Estradiol [USAN:INN]
Estradiol-17 beta
Estradiol-17-beta
Estradiol-17.beta.
Estradiol-17beta
Estradiol-3,17beta
Estradiolo
Estradiolo [DCIT]
Estradiolum
Estradiolum [INN]
Estradot
Estraldine
Estrapak 50
Estrasorb
Estrasorb (TN)
Estreva
Estrifam
Estring
Estring (TN)
Estring Vaginal Ring
Estring vaginal ring
Estroclim
Estroclim 50
Estrodiolum
Estrofem 2
Estrofem Forte
Estrogel
 
Estrogel (TN)
Estrogel HBF
Estrovite
Evamist
Evorel
Extrasorb
Femanest
Femestral
Femestrol
Femogen
Fempatch
Femtrace
Femtran
Follicyclin
Gelestra
Ginedisc
Ginosedol
GynPolar
Gynergon
Gynestrel
Gynodiol
Gynoestryl
HMS1362E07
HMS1569I04
HMS1792E07
HMS1990E07
HMS2051C17
HMS2090E18
HSDB 3589
IDI1_002118
Innofem
Innofem (TN)
KBio2_000405
KBio2_002269
KBio2_002973
KBio2_004837
KBio2_005541
KBio2_007405
KBio3_000769
KBio3_000770
KBio3_002749
KBioGR_000405
KBioGR_002269
KBioSS_000405
KBioSS_002270
LMST02010001
LS-137
Lamdiol
Lio-Oid
Lopac0_000503
MLS000069494
MLS000758312
MLS001076331
Macrodiol
Macrol
Menest
Menorest
Menostar
Microdiol
MolPort-001-794-632
NCGC00091544-00
NCGC00091544-01
NCGC00091544-02
NCGC00091544-04
NCGC00091544-05
NCGC00091544-06
NCGC00091544-07
NCGC00091544-08
NCGC00091544-09
NCGC00091544-12
NCGC00179321-01
NCGC00179321-02
NSC-9895
NSC9895
Nordicol
Oesclim
Oestergon
Oestra-1,3,5(10)-triene-3,17b-diol
Oestradiol
Oestradiol Berco
Oestradiol R
Oestradiol-17-beta
Oestradiol-17.beta.
Oestradiol-17beta
Oestradiolum
Oestrogel
Oestroglandol
Oestrogynal
Ovahormon
Ovasterol
Ovastevol
Ovociclina
Ovocyclin
Ovocycline
Ovocylin
Perlatanol
Polyestradiol
Prestwick0_000441
Prestwick1_000441
Prestwick2_000441
Prestwick3_000441
Prestwick_207
Primofol
Profoliol
Profoliol B
Progynon
Progynon DH
Progynon-DH
S-21400
S1709_Selleck
SAM001247032
SK-Estrogens
SL-1100
SMP1_000121
SMR000059126
SPBio_002421
Sandrena 1
Sandrena Gel
Sisare Gel
Spectrum5_002055
Syndiol
Systen
Tradelia
Trial SAT
Trocosone
UNII-4TI98Z838E
VIVELLE-DOT
Vagifem
Vagifem (TN)
Vivelle
Vivelle (TN)
Zerella
Zesteem
Zesteen
Zumenon
[2,4,6,7-3H]-E2
[3H]-estradiol
[3H]]estradiol
b-Estradiol
beta-Estradiol
beta-Estradiol 3-sulfate
beta-Estradiol 3-sulphate
bmse000642
cMAP_000005
cis-Estradiol
cis-Oestradiol
component of Menrium
delta-Estradiol
delta-Oestradiol
estradiol
estradiol-17beta
nchembio.168-comp3
nchembio.76-comp2
nchembio775-comp2
nchembio794-comp6
nchembio860-comp1
progynon
5
Paclitaxelapproved, vet_approvedPhase 2275833069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
6
Rucaparibapproved, investigationalPhase 1, Phase 214283173-50-29931954
Synonyms:
AG-014699
 
AG014699
PF-01367338
rucaparib
7Hormone AntagonistsPhase 212778
8HormonesPhase 213979
9MitogensPhase 21526
10Polyestradiol phosphatePhase 21283
11EstrogensPhase 22470
12Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 212767
13Estrogen Receptor AntagonistsPhase 2186
14Antineoplastic Agents, HormonalPhase 25407
15Antimitotic AgentsPhase 25498
16Albumin-Bound PaclitaxelPhase 22757
17Estrogen AntagonistsPhase 21315
18Antineoplastic Agents, PhytogenicPhase 25420
19Estradiol 17 beta-cypionatePhase 21283
20Estradiol valeratePhase 21283979-32-8
21Estradiol 3-benzoatePhase 21283
22TalazoparibPhase 226
23Kavanutraceutical1489000-38-8

Interventional clinical trials:

(show all 16)
idNameStatusNCT IDPhase
1To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian CancerRecruitingNCT02476968Phase 4
2Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes MutationsWithdrawnNCT02392676Phase 3
3Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor StatusRecruitingNCT02983799Phase 2
4An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene AmplificationRecruitingNCT01953926Phase 2
5A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)Active, not recruitingNCT01482715Phase 1, Phase 2
6Phase II Study of BMN 673Active, not recruitingNCT02286687Phase 2
7BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian CancerCompletedNCT02963688
8Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and SpecificityRecruitingNCT02518256
9Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary PresentationRecruitingNCT02664389
10Clinical Significance of Germline BRCA MutationsRecruitingNCT00579488
11EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted TherapiesRecruitingNCT02701907
12A Study of Long-Term Responders on OlaparibRecruitingNCT02489058
13Prevalence of BRCA in Patients With Ovarian CancerActive, not recruitingNCT02222883
14Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.Active, not recruitingNCT02323568
15FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic StudyNot yet recruitingNCT02984423
16Inherited Susceptible Genes Among Epithelial Ovarian CancerNot yet recruitingNCT03015376

Search NIH Clinical Center for Ovarian Cancer, Somatic

Genetic Tests for Ovarian Cancer, Somatic

About this section

Genetic tests related to Ovarian Cancer, Somatic:

id Genetic test Affiliating Genes
1 Ovarian Cancer, Somatic24 AKT1, ERBB2, PIK3CA

Anatomical Context for Ovarian Cancer, Somatic

About this section

MalaCards organs/tissues related to Ovarian Cancer, Somatic:

36
Ovary, Testes

Publications for Ovarian Cancer, Somatic

About this section

Variations for Ovarian Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Cancer, Somatic:

70
id Symbol AA change Variation ID SNP ID
1BRCA1p.Cys61GlyVAR_007757rs28897672
2BRCA1p.Cys1697ArgVAR_020702rs80356993
3BRCA1p.Arg1699TrpVAR_075666rs55770810
4CTNNB1p.Ser37CysVAR_017625rs121913403
5CTNNB1p.Thr41IleVAR_017630rs121913413
6OPCMLp.Pro95ArgVAR_055421rs137852691
7PIK3CAp.His1047ArgVAR_026192rs121913279

Clinvar genetic disease variations for Ovarian Cancer, Somatic:

5 (show all 43)
id Gene Variation Type Significance SNP ID Assembly Location
1KRASNM_004985.4(KRAS): c.35G> A (p.Gly12Asp)SNVPathogenicrs121913529GRCh37Chr 12, 25398284: 25398284
2KRASNM_033360.3(KRAS): c.34G> A (p.Gly12Ser)SNVPathogenicrs121913530GRCh37Chr 12, 25398285: 25398285
3PALB2NM_024675.3(PALB2): c.1050_1053delAACA (p.Thr351Argfs)deletionPathogenicrs515726060GRCh38Chr 16, 23635493: 23635496
4PIK3CANM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg)SNVPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
5PIK3CANM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
6ERBB2NM_001005862.2(ERBB2): c.2480A> G (p.Asn827Ser)SNVPathogenicrs28933370GRCh37Chr 17, 37881378: 37881378
7AKT1NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)SNVPathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
8NC_012920.1: m.14743A> GSNVLikely pathogenicrs527236161GRCh37Chr MT, 14743: 14743
9MT-CYBNC_012920.1: m.14753C> TSNVLikely pathogenicrs527236162GRCh38Chr MT, 14753: 14753
10MT-CYBNC_012920.1: m.14784T> CSNVLikely pathogenicrs527236163GRCh37Chr MT, 14784: 14784
11MT-CYBNC_012920.1: m.15058C> TSNVLikely pathogenicrs527236171GRCh37Chr MT, 15058: 15058
12MT-CYBNC_012920.1: m.15098A> GSNVLikely pathogenicrs527236172GRCh37Chr MT, 15098: 15098
13MT-CYBNC_012920.1: m.15314G> ASNVLikely pathogenicrs527236176GRCh37Chr MT, 15314: 15314
14MT-CYBNC_012920.1: m.15328A> GSNVLikely pathogenicrs527236178GRCh37Chr MT, 15328: 15328
15MT-CYBNC_012920.1: m.15334C> TSNVLikely pathogenicrs527236179GRCh37Chr MT, 15334: 15334
16MT-CYBNC_012920.1: m.15363A> GSNVLikely pathogenicrs527236182GRCh37Chr MT, 15363: 15363
17MT-CYBNC_012920.1: m.15453T> CSNVLikely pathogenicrs527236184GRCh37Chr MT, 15453: 15453
18MT-CYBNC_012920.1: m.15459C> TSNVLikely pathogenicrs527236186GRCh37Chr MT, 15459: 15459
19MT-CYBNC_012920.1: m.15511T> CSNVLikely pathogenicrs527236188GRCh37Chr MT, 15511: 15511
20MT-CYBNC_012920.1: m.15884G> ASNVLikely pathogenicrs527236195GRCh37Chr MT, 15884: 15884
21MT-TTNC_012920.1: m.15890C> ASNVLikely pathogenicrs527236196GRCh37Chr MT, 15890: 15890
22MT-TTNC_012920.1: m.15928G> ASNVLikely pathogenicrs527236198GRCh37Chr MT, 15928: 15928
23MT-TTNC_012920.1: m.15932T> GSNVLikely pathogenicrs527236199GRCh37Chr MT, 15932: 15932
24MT-TTNC_012920.1: m.15943T> CSNVLikely pathogenicrs527236200GRCh37Chr MT, 15943: 15943
25MT-CYBNC_012920.1: m.15061A> GSNVLikely pathogenicrs527236205GRCh37Chr MT, 15061: 15061
26MT-CYBNC_012920.1: m.15148G> ASNVLikely pathogenicrs527236206GRCh37Chr MT, 15148: 15148
27MT-CYBNC_012920.1: m.15259C> TSNVLikely pathogenicrs527236207GRCh37Chr MT, 15259: 15259
28MT-CYBNC_012920.1: m.15431G> ASNVLikely pathogenicrs193302993GRCh37Chr MT, 15431: 15431
29MT-CYBNC_012920.1: m.15452C> ASNVLikely pathogenicrs193302994GRCh37Chr MT, 15452: 15452
30MT-CYBNC_012920.1: m.15607A> GSNVLikely pathogenicrs193302996GRCh37Chr MT, 15607: 15607
31MT-CYBNC_012920.1: m.15670T> CSNVLikely pathogenicrs193302997GRCh37Chr MT, 15670: 15670
32PIK3CANM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)SNV, HaplotypePathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
33CTNNB1NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys)SNVLikely pathogenic, Pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
34PIK3CANM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys)SNVPathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
35PIK3CANM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg)SNVPathogenicrs121913272GRCh37Chr 3, 178927980: 178927980
36BRCA1NM_007294.3(BRCA1): c.1687C> T (p.Gln563Ter)SNVPathogenicrs80356898GRCh37Chr 17, 41245861: 41245861
37BRCA2NM_000059.3(BRCA2): c.5682C> G (p.Tyr1894Ter)SNVPathogenicrs41293497GRCh37Chr 13, 32914174: 32914174
38PIK3CANM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg)SNVPathogenicrs397517201GRCh37Chr 3, 178936095: 178936095
39BRCA1NM_007294.3(BRCA1): c.3375_3376delTC (p.Pro1126Ilefs)deletionPathogenicrs80357828GRCh37Chr 17, 41244172: 41244173
40BRCA1NM_007294.3(BRCA1): c.5095C> T (p.Arg1699Trp)SNVPathogenicrs55770810GRCh37Chr 17, 41215948: 41215948
41PARK2PARK2, DELdeletionPathogenicChr na, -1: -1
42OPCMLNM_001012393.2(OPCML): c.263C> G (p.Pro88Arg)SNVPathogenicrs137852691GRCh37Chr 11, 132527098: 132527098
43RRAS2NM_001177314.1(RRAS2): c.110A> T (p.Gln37Leu)SNVPathogenicrs113954997GRCh37Chr 11, 14316390: 14316390

Cosmic variations for Ovarian Cancer, Somatic:

8 (show all 20)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM28511EGFRovary,NS,carcinoma,adenocarcinomac.2108T>Cp.L703P5
2COSM12373EGFRovary,NS,carcinoma,adenocarcinomac.2159C>Tp.S720F5
3COSM53235EGFRovary,NS,carcinoma,adenocarcinomac.2481C>Tp.Y827Y5
4COSM760PIK3CAovary,NS,carcinoma,adenocarcinomac.1624G>Ap.E542K5
5COSM53224EGFRovary,NS,carcinoma,adenocarcinomac.2173A>Gp.T725A5
6COSM22992EGFRovary,NS,carcinoma,adenocarcinomac.2161G>Ap.G721S5
7COSM28286EGFRovary,NS,carcinoma,adenocarcinomac.2494C>Tp.R832C5
8COSM53225EGFRovary,NS,carcinoma,adenocarcinomac.2112G>Ap.L704L5
9COSM6224EGFRovary,NS,carcinoma,adenocarcinomac.2573T>Gp.L858R5
10COSM53228EGFRovary,NS,carcinoma,adenocarcinomac.2123A>Gp.K708R5
11COSM53232EGFRovary,NS,carcinoma,adenocarcinomac.2122A>Gp.K708E5
12COSM53266EGFRovary,NS,carcinoma,adenocarcinomac.2165C>Tp.A722V5
13COSM53229EGFRovary,NS,carcinoma,adenocarcinomac.2232C>Ap.I744I5
14COSM53213EGFRovary,NS,carcinoma,adenocarcinomac.2604A>Tp.E868D5
15COSM53231EGFRovary,NS,carcinoma,adenocarcinomac.2559C>Tp.I853I5
16COSM53230EGFRovary,NS,carcinoma,adenocarcinomac.2597A>Gp.E866G5
17COSM53265EGFRovary,NS,carcinoma,adenocarcinomac.2556G>Tp.K852N5
18COSM53226EGFRovary,NS,carcinoma,adenocarcinomac.2099A>Gp.N700S5
19COSM53264EGFRovary,NS,carcinoma,adenocarcinomac.2174C>Tp.T725M5
20COSM53227EGFRovary,NS,carcinoma,adenocarcinomac.2506C>Ap.R836S5

Expression for genes affiliated with Ovarian Cancer, Somatic

About this section
Search GEO for disease gene expression data for Ovarian Cancer, Somatic.

Pathways for genes affiliated with Ovarian Cancer, Somatic

About this section

Pathways related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50)    (show all 77)
idSuper pathwaysScoreTop Affiliating Genes
19.9AKT1, PIK3CA
29.9AKT1, PIK3CA
39.9AKT1, PIK3CA
4
Show member pathways
9.9AKT1, PIK3CA
59.6CDH1, CTNNB1
69.6AKT1, ERBB2, PIK3CA
7
Show member pathways
9.6AKT1, ERBB2, PIK3CA
89.6AKT1, ERBB2, PIK3CA
9
Show member pathways
9.5AKT1, CTNNB1, PIK3CA
10
Show member pathways
9.5AKT1, CTNNB1, PIK3CA
119.5AKT1, CTNNB1, PIK3CA
129.4AKT1, CDH1, PIK3CA
139.4AKT1, CDH1, PIK3CA
149.4CDH1, CTNNB1, PIK3CA
15
Show member pathways
9.4CDH1, CTNNB1, PIK3CA
169.4CDH1, CTNNB1, PIK3CA
179.4AKT1, BRCA1, CTNNB1
189.4AKT1, BRCA1, CTNNB1
19
Show member pathways
9.4AKT1, KRAS, PIK3CA
209.4AKT1, KRAS, PIK3CA
21
Show member pathways
9.4AKT1, KRAS, PIK3CA
22
Show member pathways
9.4AKT1, KRAS, PIK3CA
239.4AKT1, KRAS, PIK3CA
249.4AKT1, KRAS, PIK3CA
259.3CDH1, CTNNB1, ERBB2
269.3KRAS, RRAS2
27
Show member pathways
9.3AKT1, ERBB2, KRAS
28
Show member pathways
9.3AKT1, ERBB2, KRAS
29
Show member pathways
9.3AKT1, KRAS, PARK2
30
Show member pathways
9.2AKT1, CTNNB1, ERBB2, PIK3CA
319.2CDH1, ERBB2, KRAS
329.1AKT1, CDH1, ERBB2, PIK3CA
339.1CDH1, CTNNB1, KRAS
349.1AKT1, ERBB2, KRAS, PIK3CA
35
Show member pathways
9.1AKT1, ERBB2, KRAS, PIK3CA
36
Show member pathways
9.1AKT1, ERBB2, KRAS, PIK3CA
37
Show member pathways
9.1AKT1, ERBB2, KRAS, PIK3CA
38
Show member pathways
9.1AKT1, ERBB2, KRAS, PIK3CA
399.1AKT1, CDH1, CTNNB1, PIK3CA
409.0ERBB2, KRAS, RRAS2
41
Show member pathways
9.0AKT1, KRAS, RRAS2
42
Show member pathways
9.0AKT1, KRAS, RRAS2
43
Show member pathways
9.0AKT1, KRAS, RRAS2
449.0AKT1, CTNNB1, KRAS, PIK3CA
459.0AKT1, CTNNB1, KRAS, PIK3CA
469.0BRCA1, ERBB2, KRAS, PIK3CA
479.0AKT1, BRCA1, KRAS, PIK3CA
488.8AKT1, CDH1, CTNNB1, KRAS
49
Show member pathways
8.7AKT1, KRAS, PIK3CA, RRAS2
50
Show member pathways
8.7AKT1, KRAS, PIK3CA, RRAS2

GO Terms for genes affiliated with Ovarian Cancer, Somatic

About this section

Cellular components related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1apical junction complexGO:004329610.4CDH1, CTNNB1
2catenin complexGO:001634210.4CDH1, CTNNB1
3flotillin complexGO:001660010.4CDH1, CTNNB1
4focal adhesionGO:00059259.3CDH1, CTNNB1, KRAS, RRAS2
5protein complexGO:00432348.2AKT1, BRCA1, BRCA2, CTNNB1, PARK2
6plasma membraneGO:00058867.6AKT1, BRCA1, CDH1, CTNNB1, ERBB2, KRAS

Biological processes related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 30)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of release of cytochrome c from mitochondriaGO:009020110.5AKT1, PARK2
2negative regulation of reactive oxygen species metabolic processGO:200037810.4BRCA1, PARK2
3regulation of myelinationGO:003164110.4AKT1, CTNNB1
4cellular response to lithium ionGO:007128510.4CDH1, CTNNB1
5positive regulation of histone H3-K4 methylationGO:005157110.3BRCA1, CTNNB1
6protein K6-linked ubiquitinationGO:008502010.3BRCA1, PARK2
7epithelial tube branching involved in lung morphogenesisGO:006044110.3CTNNB1, KRAS
8positive regulation of nitric-oxide synthase activityGO:005100010.3AKT1, KRAS
9phosphatidylinositol-mediated signalingGO:004801510.3AKT1, ERBB2, PIK3CA
10cellular processGO:000998710.2CTNNB1, RRAS2
11cellular response to growth factor stimulusGO:007136310.2AKT1, CTNNB1, ERBB2
12regulation of phosphatidylinositol 3-kinase signalingGO:001406610.2AKT1, ERBB2, PIK3CA
13negative regulation of neuron deathGO:190121510.1AKT1, CTNNB1, PARK2
14negative regulation of neuron apoptotic processGO:004352410.0KRAS, PARK2, PIK3CA
15liver developmentGO:000188910.0CTNNB1, KRAS, PIK3CA
16striated muscle cell differentiationGO:005114610.0AKT1, KRAS
17chordate embryonic developmentGO:004300910.0BRCA1, BRCA2
18DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.0BRCA1, BRCA2
19cellular response to indole-3-methanolGO:007168110.0BRCA1, CDH1, CTNNB1
20positive regulation of protein phosphorylationGO:00019349.9AKT1, ERBB2, KRAS
21inner cell mass cell proliferationGO:00018339.8BRCA2, PALB2
22vasculature developmentGO:00019449.8CTNNB1, PIK3CA
23ERBB2 signaling pathwayGO:00381289.8AKT1, ERBB2, KRAS, PIK3CA
24chromosome breakageGO:00310529.4BRCA1, BRCA2, PALB2
25DNA synthesis involved in DNA repairGO:00007319.4BRCA1, BRCA2, PALB2
26double-strand break repair via homologous recombinationGO:00007249.4BRCA1, BRCA2, PALB2
27cell proliferationGO:00082839.4AKT1, BRCA2, CTNNB1, ERBB2
28response to estradiolGO:00323559.4BRCA1, BRCA2, CTNNB1
29positive regulation of gene expressionGO:00106289.2BRCA1, CTNNB1, ERBB2, KRAS, PARK2
30strand displacementGO:00007329.1BRCA1, BRCA2, PALB2

Molecular functions related to Ovarian Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1GTPase activating protein bindingGO:00327949.7AKT1, CDH1
2enzyme bindingGO:00198999.3AKT1, BRCA1, CTNNB1, PARK2

Sources for Ovarian Cancer, Somatic

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet